Glenmark Pharmaceuticals has added another product to its growing U.S. respiratory lineup. The company confirmed on August 20, 2026, that the U.S. Food and Drug Administration has approved its fluticasone propionate nasal spray, USP, 0.05 mg (50 mcg)/spray - a generic equivalent of Haleon's well-known Flonase Nasal Spray, used to relieve nasal symptoms tied to allergic rhinitis.
A Step Forward in Glenmark's Respiratory Push
Company leadership framed the approval as part of a broader strategy to deepen its footprint in the U.S. respiratory market. Marc Kikuchi, who heads Glenmark's North America business, described the approval as building on ground the company has already laid in this therapeutic area, while reiterating a focus on making effective treatments more accessible and affordable for patients and providers alike.
Glenmark Pharmaceuticals Inc., USA will handle distribution of the new product. The company has not yet disclosed pricing details or a launch timeline.
How the Drug Works
Fluticasone propionate belongs to a class of medications known as intranasal corticosteroids. Rather than working systemically, it acts directly on nasal tissue to calm local inflammation. This targeted action helps ease a range of allergy symptoms - congestion, sneezing, a runny or itchy nose, and watery, itchy eyes. Patients typically notice initial relief within hours, with the medication's full benefit developing over the following days.
The reference product, Flonase, is approved for use in patients aged 12 and older and works by counteracting several of the body's inflammatory triggers, including histamine, prostaglandins, cytokines, tryptases, chemokines, and leukotrienes. Clinical research behind the original branded product - two randomized, double-blind, placebo-controlled trials - established that its effects hold up over a full 24-hour period.
Not the First Generic on the Market
Glenmark's approval doesn't break new ground in terms of drug availability - it enters a category that has already been genericized for two decades. The FDA granted its first approval for a generic prescription version of fluticasone propionate nasal spray back in 2006, to Roxane Laboratories. What Glenmark's approval does add is another manufacturer-backed, FDA-vetted option in an already competitive space.
Flonase itself has a longer regulatory history. Originally cleared as a prescription-only treatment in October 1994, it made the switch to over-the-counter status in July 2014 - a milestone that made it the first OTC nasal spray approved to treat both nasal and eye-related allergy symptoms simultaneously. Haleon US Holdings LLC currently holds the branded New Drug Application that Glenmark's generic references.
What the Approval Pathway Means
Because Glenmark's product moved through the FDA's generic drug pathway rather than an independent clinical development program, no new efficacy or safety data accompanies this approval. Instead, the pathway requires manufacturers to demonstrate that their product matches the reference drug's active ingredient, strength, dosage form, and route of administration, and that it performs comparably in the body - a standard known as bioequivalence. In practical terms, that means patients and providers can expect the same therapeutic performance from Glenmark's version as they would from branded Flonase.
This article is based on Glenmark Pharmaceuticals' August 20, 2026 announcement and related public reporting on the FDA approval.
Sign in to leave a comment.